GLYCINE RECEPTOR ANTIBODIES IN 2 CASES OF NEW, ADULT-ONSET EPILEPSY

Autoimmune encephalitides have been recognized in association with antibodies targeting neuronal surface antigen antibodies [NSAbs]. Glycine receptors (GlyRs) are fundamental in motor neuron excitability, and antibodies against GlyRα1 (GlyR Abs) were identified in a case of progressive encephalomyelitis with rigidity and myoclonus (PERM) and subsequently in other cases related to the stiff person syndrome spectrum. GlyRs are expressed mainly in the spine and brainstem but also in the hippocampus. Here we report 2 patients with subacute onset of refractory temporal lobe seizures associated with behavioral changes and memory deficits whose sera were positive for GlyR Abs.

Case reports. Patient 1. A 25-year-old man presented with a generalized convulsive status epilepticus (GCSE). Apathy and anxiety were noted over a few days. Status epilepticus was controlled with propofol. Vital signs, neurologic examination, routine blood tests, CSF analysis, and brain MRI were normal. Postictal EEG disclosed diffuse slow abnormalities. On day 2, GCSE recurred and he was transferred to the intensive care unit (ICU). Over the following days, when sedation was withdrawn, seizures continued despite IV phenytoin and levetiracetam. An EEG performed on day 7 showed an ictal discharge over right temporal leads, significant depression, and long-term verbal memory impairment, and the patient was transferred to the rehabilitation department and discharged after 8 weeks. By telephone interview 5 months after discharge, he was seizure-free on the same antiepileptic drug (AED) combination.

Patient 2. A 41-year-old woman presented with a 3-month history of daily short-lasting (seconds) episodes characterized by abdominal pain followed by lightheadedness, nausea, goose bumps, and sensation of uncomfortable breathing. In the same period she started complaining of short-term memory difficulty. EEG revealed ictal discharges over right temporal leads (figure, C). 3T brain MRI showed a mild asymmetry of hippocampal volume (right 5.80 mL; left 5.24 mL; normal value 4.48–6.41 mL) with no different signal intensities on fluid-attenuated inversion recovery and T2-weighted images. She was given different AEDs (oxcarbazepine, lacosamide, valproate) without benefit. Four months later she was admitted because of persisting seizures with new onset of sudden spasms involving the whole body. Neurologic examination revealed mild cerebellar ataxia. Neuropsychological examination showed severe impairment of attention as well as short- and long-term verbal memory, moderate anxiety, and depression. Polygraphy disclosed sudden diffuse spasms, both spontaneous and induced by eye-opening or intermittent photic stimulation, with no EEG correlate (figure, D). CSF analysis was normal; oligoclonal bands were absent. Neoplastic markers, systemic autoimmunity, serum “onconeural,” GAD65, NMDAR, AMPAR, GABABR, and voltage-gated potassium channel (VGKC)–complex autoantibodies was negative. Brain MRI was uninformative. On day 17, IV steroid (methylprednisolone 1 g/d for 7 days) was started, and 3 days later seizure frequency declined. Off sedation, the patient had only sporadic focal seizures. However, when steroids were tapered, status epilepticus reappeared. IV immunoglobulin (IVIg) 0.4 g/kg/d for 5 days was started with marked improvement, and on day 40 he was discharged from the ICU. Seizures were controlled with a combination of phenobarbital, phenytoin, and zonisamide. EEG showed diffuse slow waves while brain MRI revealed a T2-weighted hyperintensity with mild swelling of right hippocampus, likely due to local edema induced by status epilepticus (figure, B). A wider autoantibody screening with a live cell-based assay subsequently showed GlyR-Ab positivity in serum; CSF was not available for further testing. The patient was transferred to the rehabilitation department and discharged after 8 weeks. By telephone interview 5 months after discharge, he was seizure-free on the same antiepileptic drug (AED) combination.
was gradually tapered off over a period of 3 months. The patient is currently receiving only the above-mentioned antiepileptic treatment and refuses further trial with IVIg.

**Discussion.** The clinical picture of our 2 patients is in keeping with limbic encephalitis (LE). Patient 2 also displayed spontaneous and stimulus-sensitive spasms suggesting rhomboencephalitis and the diagnosis of PERM. It is thought that early diagnosis of LE should be considered in patients with multiple mesiotemporal seizures even in the absence of typical MRI abnormalities. The possibility of an NSAb-associated autoimmune encephalitis justified a trial of immunomodulatory treatment in both patients and was further supported by the finding of serum GlyR-Abs. Immunomodulation was effective in controlling symptoms in patient 1. In patient 2 IVIg provoked disappearance of spasms but only a mild reduction of seizure frequency and had no effect on attention and memory impairment; steroids were ineffective.

To our knowledge, seizures were reported in 1 patient with GlyR-Ab/PERM and another had seizures with hippocampal inflammatory involvement, but NMDAR-Ab coexisted. Of course, we cannot exclude the possibility that other antibodies were present and could explain hippocampal involvement in our patients. The antibody assay employed measured Ab to the $\alpha_1$ subunit, but these antibodies often cross-react with hippocampal GlyRs $\alpha_2$ and 3 subunits. Of note, GlyR expression is altered in patients with temporal lobe epilepsy and GlyR-Abs were identified in 3% of a large cohort of patients with epilepsy.

We suggest that screening for NSAb could include GlyR-Ab in patients with autoimmune LE with seizures.
From the Department of Neurology (L.Z., M.Z., B.G.), Ospedale Ca’Foncello, Treviso, Italy; Magna Græcia University of Catanzaro and Regional Epilepsy Centre, Bianchi-Melacrino-Morelli Hospital (E.F., V.C., U.A.), Reggio Calabria, Italy; Ospedale di Arzignano ULSS5 (C.A., A.C., E.D.M., M.M.) Ovest Vicentino, Italy; and Nuffield Department of Clinical Neurosciences (M.I.L., P.W., M.W., A.V.), University of Oxford, UK.

Author contributions: Luigi Zuliani, Edoardo Ferlazzo, Umberto Aguglia, Angela Vincent: interpretation of the data, drafting and revision of the manuscript. Cinzia Andrigo, Alessandro Casano, Victoria Cianci, Marco Zoccarato, Maria Isabel Leite, Patrick Waters, Mark Woodhall, Ernesto Della Mora, Michele Merra, Bruno Giometto: interpretation of the data, revision of the manuscript.

Study funding: No targeted funding reported.

Disclosure: L. Zuliani, C. Andrigo, A. Casano, V. Cianci, M. Zoccarato, M. Woodhall, E. Della Mora, M. Merra, B. Giometto, and U. Aguglia report no disclosures. E. Ferlazzo has received honoraria for travel and speaking from UCB. M.I. Leite is supported by NHS National Specialised Commissioning Group for Neuromyelitis optica, UK; and by NIHR Oxford Biomedical Research Centre and has received speaking honoraria from Biogen Idec and travel and educational grants from Biogen Idec and UK. P. Waters has received speaking honoraria from Biogen Idec and Euroimmun AG; is a review editor for Frontiers in Molecular Innate Immunity; and holds a patent for assays for the detection of antibodies to LG1, Caspr2, and TAG-1. A. Vincent has received honoraria for travel and speaking from Baxter International Inc and Biogen Inc; is on the advisory board and is an associate editor for Brain; holds a patent with Oxford University for VGKC complex antibodies licensed to Euroimmun AG; serves on the advisory board and is an associate editor for Neurology; holds a patent with Oxford University for VGKC complex antibodies licensed to Euroimmun AG; helps to edit the protocols for Athena Diagnostics, Euroimmun AG, Blackwell Publishing, and Mac Keith Press; has consulted with Athena Diagnostics for assessing antibody assays; and has received research support from NIHR. Go to Neurology.org/nn for full disclosures. The Article Processing Charge was paid by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Received March 23, 2014. Accepted in final form May 28, 2014.

Correspondence to Dr. Zuliani: lugiizuliani77@gmail.com


Glycine receptor antibodies in 2 cases of new, adult-onset epilepsy
Luigi Zuliani, Edoardo Ferlazzo, Cinzia Andrigo, et al.

*Neurol Neuroimmunol Neuroinflamm* 2014;1;
DOI 10.1212/NXI.0000000000000016

This information is current as of July 3, 2014